Ketosis as a Treatment for Severe Mental Illness: A Critical Review of Preclinical and Clinical Data.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical and clinical data without systematic search methodology
PubMed 42614443 · doi:10.1007/s40501-026-00394-z
What was done
The authors critically reviewed preclinical and clinical evidence evaluating ketosis-inducing interventions—such as ketogenic diets, exogenous ketones, medium-chain triglycerides, and fasting—for severe mental illnesses including depression, bipolar disorder, and schizophrenia.
What was found
The abstract reports no numerical data. Uncontrolled trials suggested beneficial mental and metabolic effects from ketogenic diets, but the only reported randomized controlled trial in treatment-resistant depression found a small between-group antidepressant difference favoring a modified ketogenic diet over a phytochemical control diet that did not achieve statistical significance. Furthermore, circulating ketone levels did not correlate with psychiatric outcomes. Exogenous ketones and oral medium-chain triglycerides have not been tested in clinical populations with severe mental illness.
Why it matters
This review clarifies that despite substantial interest in metabolic psychiatry, clinical evidence supporting ketosis as an active therapeutic mechanism for severe mental illness remains preliminary and unproven in controlled trials.
Limits
The abstract does not state the total number of studies reviewed or search parameters. Existing human data are limited by reliance on uncontrolled studies subject to expectation bias and confounding, an absence of mechanistic ketone-outcome correlation data, and an absence of clinical trials evaluating non-dietary ketosis-inducing agents.